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Abstract Tau hyperphosphorylation is a central event in the
development of Alzheimer’s Disease (AD). Protein phosphatase
2A (PP2A) heterotrimer formation is necessary for efficient
dephosphorylation of the tau protein. S-Adenosylmethionine-
dependent carboxyl methylation is essential for the assembly of
PP2A heterotrimers. Epidemiological evidence indicates that
elevated plasma homocysteine is an independent risk factor for
AD. Homocysteine is a key intermediate in the methyl cycle and
elevated plasma homocysteine results in a global decrease in
cellular methylation. We propose that the PP2A methylation
system is the link relating elevated plasma homocysteine to
AD. ß 2002 Published by Elsevier Science B.V. on behalf of
the Federation of European Biochemical Societies.
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1. Protein phosphatase 2A (PP2A) and Alzheimer’s Disease
(AD)
In this paper, we will use evidence from the basic and the
clinical literature to formulate a hypothesis regarding the eti-
ology of AD that provides an explanation for the recent ob-
servation that elevated plasma homocysteine (Hcy) is an in-
dependent risk factor for AD [1]. Our proposition that
elevated plasma Hcy is causally involved in AD pathogenesis
has strong implications for the role that nutrition may play in
the development of the disease. AD is a progressive neurode-
generative disease associated clinically with memory impair-
ment and decreased cognitive function (see [2] for a recent
review of AD). Post-mortem brains of AD patients display
two pathological hallmarks: neuritic plaques and neuro¢bril-
lary tangles (NFTs). The plaques are composed of extracellu-
lar deposits of the amyloid L-protein (AL), a polypeptide de-
rived from proteolytic cleavage of the L-amyloid precursor
protein (LAPP) [3]. NFTs are found primarily within the
cell and essentially comprise ¢laments of tau protein [4].
Normally, tau is found predominantly in the axons of neu-
rons [5] where it stabilizes microtubules (MTs) and promotes
their polymerization [6]. MTs play a major role in maintaining
the cellular architecture of neurons and are largely responsible
for axonal transport (see [7] for a recent review of MT-based
transport in neurons). The integrity of MT structure is critical
for proper neuronal function and synaptic transmission. The
tau found in NFTs is abnormally hyperphosphorylated [8].
This high level of phosphorylation appears to precede and
promote NFT formation [9]. Hyperphosphorylated tau is
also found in the cytosol of NFT-containing neurons [10].
Phosphorylation inhibits tau’s ability to bind and stabilize
MTs [11,12]. Hyperphosphorylated tau has a dominant neg-
ative e¡ect on MTs insofar as it binds normal tau as well as
MT-associated proteins 1 and 2, thereby interfering with the
ability of these three proteins to stabilize MTs [13]. These data
help account for the observation that neurons that contain
NFTs lack MTs [14]. Thus, the cytoskeletal disruption
brought about by hyperphosphorylated tau provides an ex-
planation for the neurodegeneration associated with AD.
Genetic evidence supports the conclusion that tau hyper-
phosphorylation is a critical event in the development of de-
mentia [15]. Mutations in the tau gene underlie several fami-
lial neurodegenerative diseases where ¢lamentous deposits of
hyperphosphorylated tau have been observed in the absence
of amyloid plaques, most notably frontotemporal dementia
and Parkinsonism linked to chromosome 17 [15]. Though
under some conditions AL accumulation has been shown to
promote NFT formation [16,17], plaque formation is not
essential for NFT-associated dementias, the so-called ‘tau-
opathies’ (see [18] for a recent review of these neurodegenera-
tive diseases).
Tau hyperphosphorylation results from an imbalance be-
tween kinase and phosphatase activities (for a recent review
see [19]). Phosphorylation is catalyzed by the neuronally en-
riched serine/threonine kinases glycogen synthase kinase 3L
(GSK-3L) [20] and cyclin-dependent kinase 5 (CDK5) [21].
Tau dephosphorylation is mediated by PP2A [22]. Recent re-
sults suggest that a decrease in PP2A activity, rather than an
increase in kinase activity, is crucial for the elevated levels of
tau phosphorylation associated with NFT formation [23].
Work in mouse brain indicates a general decrease in PP2A
expression levels with age [24], and PP2A expression has been
found to be signi¢cantly reduced in the hippocampus of AD
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brains relative to control brains [25]. Treatment of cultured
human neurons with the PP2A inhibitor okadaic acid results
in tau hyperphosphorylation, reduced binding of tau to MTs,
MT depolymerization, and axonal degeneration [26]. More-
over, starved mice display a pattern of tau hyperphosphory-
lation similar to that found in AD brains, and this hyper-
phosphorylation appears to result from decreased PP2A
activity towards tau rather than increased kinase activity
[23]. In fact, the tau phosphorylating activities of CDK5
and GSK-3L decreased under these conditions. Thus, reduced
PP2A activity towards tau must be part of any model ac-
counting for NFT formation during the progression of AD.
PP2A is a multimeric protein complex consisting of a 65-
kDa A subunit that acts as a sca¡old for the association of a
36-kDa catalytic C subunit and one of a variety of regulatory
B subunits (see [27] for a general review of PP2A structure
and function). B subunits control the substrate speci¢city and
subcellular localization of PP2A. BK, the major regulatory
subunit in brain, causes PP2A to bind to MTs and tau and
dramatically increases the enzyme’s activity towards the tau
protein [28]. The highly conserved carboxyl-terminal sequence
of the PP2A C subunit is a focal point for phosphatase reg-
ulation [27]. This is the site of a reversible methyl esteri¢cation
reaction that controls the formation of ABKC heterotrimers
[29].
2. Role of PP2A methylation and the methyl cycle in AD
PP2A methylation is controlled by a speci¢c, S-adenosyl-
methionine (SAM)-dependent methyltransferase [30] and a
speci¢c methylesterase [31]. Methylation of AC dimers has
been shown to dramatically increase their a⁄nity for BK reg-
ulatory subunits [29]. The assembly of ABKC heterotrimers
proceeds as a multistep process with AC dimer methylation
followed by binding of regulatory BK subunits (Fig. 1). Given
the critical role of BK in directing PP2A activity towards tau
[28], one would expect that a decrease in PP2A methylation
could lead to tau hyperphosphorylation, NFT formation, and
neurodegeneration.
Over the last several years data have emerged in the clinical
literature demonstrating a signi¢cant correlation between ele-
vated plasma Hcy and the occurrence of AD [1,32,33].
Though elevated plasma Hcy has long been established as
an independent, graded risk factor for cardiovascular disease
[34,35], the correlation with AD is a fairly recent observation.
An early study found that patients with pathologically con-
¢rmed AD had signi¢cantly elevated plasma Hcy levels rela-
tive to a control group [33]. Hcy levels in the AD patients
remained stable over time even as the disease progressed,
suggesting that the elevation was not a result of neurodegen-
eration or AD-associated behavioral changes. Furthermore,
patients with high plasma Hcy displayed more rapid neural
atrophy over the course of three years than did patients with
lower levels. More recent data from a prospective study pro-
vides convincing evidence that a rise in plasma Hcy precedes
the onset of AD and is an independent risk factor for the
disease [1]. Baseline plasma Hcy levels were measured in
1092 non-demented patients and the occurrence of AD in
this group was followed for several years. After adjusting
for other AD risk factors, the authors found that plasma
Hcy levels greater than 14 WM coincided with a roughly
two-fold increased risk of developing AD. Further, elevated
plasma Hcy appears to be a graded risk factor, with a 40%
increased risk of developing AD associated with each 5 WM
incremental rise. These studies indicate a connection between
high plasma Hcy and AD. Clearly, insight into the mechanism
underlying the Hcy^AD correlation could give important
clues for treatment of the disease.
Hcy is central to the methyl cycle (Fig. 2) and plays an
important role in cellular methylation (see [36] for a recent
review of Hcy metabolism). SAM-dependent methylation re-
actions result in the production of S-adenosylhomocysteine
(SAH) (reaction 2), which is subsequently cleaved by the en-
zyme SAH hydrolase to adenosine and Hcy (reaction 3). The
SAH hydrolase reaction is reversible with the equilibrium ac-
tually favoring the condensation of Hcy and adenosine to
form SAH [37]. SAH is a potent competitive inhibitor of
Fig. 1. Summary of PP2A methylation and tau phosphorylation.
The PP2A methyltransferase, MTase, binds to and methylates AC
dimers while the methylesterase, MEase, removes the modi¢cation.
Methylation of AC dimers dramatically increases their a⁄nity for
BK subunits. The ABKC heterotrimer is the major tau dephosphory-
lating activity in vivo and phosphorylation appears to be controlled
primarily by GSK-3L and CDK5.
Fig. 2. Key to enzymes: 1: methionine adenosyl transferase;
2: SAM-dependent methyltransferases; 3: SAH hydrolase; 4: cysta-
thionine L-synthase; 5: cystathionine Q lyase; 6: betaine homocys-
teine methyltransferase; 7: methionine synthase.
FEBS 26071 26-4-02
S.B. Vafai, J.B. Stock/FEBS Letters 518 (2002) 1^42
virtually all methyltransferase enzymes and accumulation of
Hcy is associated, via an increase in SAH, with a global de-
crease in cellular methylation [38^40]. These results are con-
sistent with the hypothesis that Hcy facilitates the progression
of AD by inhibiting PP2A methylation in brain since de-
creased PP2A methylation will result in reduced ABKC hetero-
trimer formation and thereby lead to tau hyperphosphoryla-
tion, NFT formation, neurodegeneration, and dementia.
Thus, PP2A methylation provides the link between elevated
plasma Hcy and AD.
Hcy is eliminated by two mechanisms. It can be methylated
to regenerate methionine or it can be converted to cysteine via
the transsulfuration pathway (Fig. 2). Hcy can be methylated
by betaine Hcy methyltransferase (reaction 6), an enzyme
present only in liver and kidney [41]. Virtually all tissues con-
vert Hcy to methionine via a vitamin B12-dependent enzyme
that transfers a methyl group from 5-methyltetrahydrofolate
to Hcy (reaction 7). Low levels of folate or vitamin B12 will
decrease methionine synthesis from Hcy (reaction 7) in turn
compromising the production of SAM from methionine (re-
action 1). Thus, folate or vitamin B12 de¢ciency could reduce
cellular methylation due to both a decrease in the availability
of SAM as well as product inhibition by elevated SAH. Hcy is
removed from the methyl cycle by a series of reactions cata-
lyzed by vitamin B6-dependent enzymes (reactions 4 and 5).
Plasma Hcy levels tend to increase with age and the primary
determinants appear to be plasma folate, vitamin B12 and
vitamin B6 [42]. Given the prominent role that vitamin B12,
vitamin B6, and folate play in Hcy metabolism, it seems likely
that de¢ciency for these vitamins underlies the observed ele-
vation of Hcy.
Though our hypothesis clearly connects elevated plasma
Hcy to tau hyperphosphorylation, NFT formation, and neu-
rodegeneration, the role of AL plaque formation is not as
clear. The proteolytic events that convert LAPP to toxic AL
peptides occur in the trans-Golgi network [43]. LAPP can
travel in axons along MT tracks carried in kinesin-driven
vesicles [44]. Inhibition of anterograde axonal transport re-
sults in the accumulation of LAPP in the cell body [45], where
conversion to AL takes place [43]. This would be expected to
result in increased AL production, secretion, and plaque for-
mation [45]. The MT depolymerization associated with tau
hyperphosphorylation will also inhibit anterograde axonal
transport resulting in LAPP accumulation in the cell body.
Therefore, the loss of MT-based transport systems provides
a potential link between tau hyperphoshorylation and AL
plaque formation.
We propose that elevated Hcy causes tau hyperphosphor-
ylation, NFT formation, neurodegeneration, dementia, and
AL plaque formation via a decrease in PP2A methylation.
Plasma Hcy levels are generally decreased by dietary supple-
ments of folate, vitamin B12, and vitamin B6 [46]. By provid-
ing evidence for a causal involvement of Hcy in AD patho-
genesis, our hypothesis suggests that lowering plasma Hcy by
such dietary intervention may help to reduce occurrence of
AD or slow the disease’s progress. Grain products in the
United States have been forti¢ed with folate since 1998 and
this is su⁄cient to decrease Hcy levels in some individuals
[47]. It will be interesting to see if this policy alters the fre-
quency with which AD occurs in the future. One can imagine
that metabolic, genetic, and behavioral factors that lead to
increased plasma Hcy are causal events in many instances of
AD. Our hypothesis should serve as a foundation for under-
standing the molecular basis of these e¡ects and it raises the
possibility for the development of anti-AD pharmaceuticals
by screening for agents that modulate methylation of PP2A.
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